肝硬化伴食管胃静脉曲张患者内镜治疗后出血的危险因素分析

肝脏 ›› 2022, Vol. 27 ›› Issue (5): 526-530.

肝硬化伴食管胃静脉曲张患者内镜治疗后出血的危险因素分析

方青青, 陈颖, 陈炜, 简佑容, 李煜, 祝子华, 沈丹杰, 陈世耀, 李锋

201199 上海复旦大学附属闵行医院(上海市闵行区中心医院)消化内科(方青青,陈颖,陈炜,简佑容,李煜,祝子华,沈丹杰);复旦大学附属中山医院消化科(陈世耀,李锋)

收稿日期:2022-02-25 出版日期:2022-05-31 发布日期:2022-07-13
通讯作者: 李锋,Email: 13661654285@163.com

Risk factors of rebleeding after endoscopic treatment for esophagogastric varices in liver cirrhosis patients

FANG Qing-qing¹, CHEN Ying¹, CHEN Wei¹, JIAN You-rong¹, LI Yu¹, ZHU Zi-hua¹, SHEN Dan Jie¹, CHEN Shi-yao, LI Feng^1,2

1. Department of Gastroenterology,Minhang Hospital, Fudan University, Shanghai 201199,China;
2.Department of Gastroenterology,Zhongshan Hospital,Fudan University,Shanghai 200032,China

Received:2022-02-25 Online:2022-05-31 Published:2022-07-13
Contact: LI Feng, Email: 13661654285@163.com

摘要/Abstract

摘要： 目的探讨肝硬化伴食管胃静脉曲张患者行内镜治疗后的出血率及出血相关的危险因素。方法回顾性分析2018年12月—2021年6月复旦大学附属闵行医院消化内科收治的因肝硬化并食管胃静脉曲张首次行内镜下治疗的住院患者的临床资料;根据治疗后随访期间是否出血分为出血组和未出血组,比较两组间的临床特征、实验室和影像检查结果、血流动力学参数以及内镜治疗情况的差异;并采用Cox回归模型探讨静脉曲张内镜治疗后出血的独立危险因素。结果共纳入75例患者,其中15例(20%)治疗后随访期间有出血。出血组和未出血组比较,其中内镜治疗前有消化道出血的54例患者中14例出现治疗后出血,出血率25.93%(P=0.04);合并有门静脉血栓24例,治疗后出血8例,出血率33.33%(P=0.048);乙型肝炎肝硬化患者35例,有11例出现治疗后出血,出血率31.43%(P=0.021);Child A级24例,治疗后出血4例,Child B级47例,治疗后出血8例,Child C级4例,治疗后出血3例(P=0.018);内镜治疗前有消化道出血、门静脉血栓、乙型肝炎肝硬化、Child-Pugh分级是内镜下治疗后出血的危险因素。Cox回归分析显示,Child-Pugh分级(95%CI=1.273～12.879,HR=4.0487,P=0.018)是静脉曲张内镜治疗后随访期间出血的独立危险因素。结论 Child-Pugh分级是肝硬化伴食管胃静脉曲张患者内镜治疗后出血的独立危险因素。对肝功能差的患者进行食管胃静脉曲张内镜治疗需慎重。

关键词: 肝硬化, 食管胃底静脉曲张, 内镜下治疗, 再出血

Abstract: Objective To investigate the rebleeding rate and the risk factors of rebleeding after endoscopic treatment for esophagogastric varices in liver cirrhosis patients. Methods Retrospective analysis the clinical data of patients who with liver cirrhosis and accept esophageal variceal ligation and/or gastric variceal obliteration treatment for the first time from June 2018 to June 2021, and hospitalized in the Department of Gastroenterology of Minhang Hospital, Fudan University. According to whether there was bleeding during the follow-up period after treatment, they were divided into bleeding group and non bleeding group. The clinical features, laboratory results, imaging findings, hemodynamic parameters and endoscopic treatment were compared between the two groups. Cox regression model was used to explore the independent risk factors of bleeding after endoscopic treatment of varices. Results A total of 75 patients were included, of which 15 (20%) had bleeding during the follow-up after treatment. Compared with the non bleeding group, 14 of the 54 patients who with gastrointestinal bleeding before endoscopic treatment had bleeding after treatment, the bleeding rate was 25.93%, P=0.04. There were 24 cases complicated with portal vein thrombosis, while 8 cases were bleeding after treatment, the bleeding rate was 33.33%, P=0.048. In 35 cases of cirrhosis after hepatitis B, 11 cases had bleeding after treatment, the bleeding rate was 31.43%, P=0.021. And 24 cases of child a, 4 cases of bleeding after treatment, 47 cases of Child B, 8 cases of bleeding after treatment, 4 cases of child C, 3 cases of bleeding after treatment, P=0.018. Gastrointestinal bleeding occurred before endoscopic treatment, the portal vein thrombosis, cirrhosis after hepatitis B and Child-Pugh are risk factors for bleeding after endoscopic treatment, the difference between the two groups was statistically significant. Cox regression analysis showed that Child-Pugh grade (95%CI=1.273～12.879, HR=4.0487, P=0.018) was an independent risk factor for bleeding during follow-up after endoscopic treatment of varices. Conclusion Child Pugh grade is an independent risk factor for bleeding after endoscopic treatment in patients with liver cirrhosis and esophagogastric varices. Endoscopic treatment for gastroesophageal varices in patients who with poor liver function should be cautious.

Key words: Cirrhosis, Esophagogastric varices, Endoscopic treatment, Rebleeding

方青青, 陈颖, 陈炜, 简佑容, 李煜, 祝子华, 沈丹杰, 陈世耀, 李锋. 肝硬化伴食管胃静脉曲张患者内镜治疗后出血的危险因素分析[J]. 肝脏, 2022, 27(5): 526-530.

FANG Qing-qing, CHEN Ying, CHEN Wei, JIAN You-rong, LI Yu, ZHU Zi-hua, SHEN Dan Jie, CHEN Shi-yao, LI Feng. Risk factors of rebleeding after endoscopic treatment for esophagogastric varices in liver cirrhosis patients[J]. Chinese Hepatolgy, 2022, 27(5): 526-530.

参考文献

[1] Nett A, Binmoeller KF. Endoscopic Management of Portal Hypertension-related Bleeding. Gastrointest Endosc Clin N Am, 2019, 29: 321-337.
[2] 徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 临床肝胆病杂志, 2016, 32: 203-219.
[3] de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63: 743-752.
[4] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志,2019, 27: 846-865.
[5] 中华医学会外科学分会脾及门静脉高压外科学组, 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版). 中华消化外科杂志, 2019, 12: 1087-1093.
[6] Mishra SR, Sharma BC, Kumar A, et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol, 2011, 54: 1161-1167.
[7] Hernaez R, Kramer JR, Liu Y, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol, 2019, 70: 639-647.
[8] Mumtaz K, Issak A, Porter K, et al. Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic Patients: A Model Based on the Administrative Database. Hepatology, 2019, 70: 630-639.
[9] Cao Z, Liu Y, Cai M, et al. The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis. Am J Gastroenterol, 2020, 115: 2026-2035.
[10] 杜静园, 颜华东. 不同病因肝硬化失代偿患者临床特征及长期预后危险因素的前瞻性队列研究. 肝脏, 2021, 26: 140-146.
[11] 叶秀芳, 马乾凤, 王剑君, 等. 肝脏流入道血流动力学变化与酒精性肝病的相关性研究. 宁夏医学杂志, 2008,30: 974-976.
[12] Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol, 2011, 54: 78-88.
[13] Wang J, Zhang Z, Yan X, et al. Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. Dig Liver Dis, 2019, 51: 1172-1178.
[14] Fujita K, Nomura T, Morishita A, et al. Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. J Clin Med, 2019, 8: 1258.
[15] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65: 310-335.
[16] 中国门静脉高压诊断与监测研究组, 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专委会, 等. 中国肝静脉压力梯度临床应用专家共识(2018年版). 实用肝脏病杂志, 2019, 22: 321-332.